학술논문
ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia
Document Type
Abstract
Author
Source
In Atherosclerosis August 2022 355
Subject
Language
ISSN
0021-9150